Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

AGL

Agilon Health Appoints Tim O'Rourke as CEO

Agilon Health said April 27 it appointed Tim O’Rourke as chief executive officer and a board member, effective May 7, replacing Ronald A. Williams, who will remain chairman.

The leadership change comes after a year in which the company said it strengthened its foundation, improved data and technology capabilities, supported partners in clinical pathways, reshaped key payor relationships and worked to make partnerships more sustainable for physicians, patients and payors.

O’Rourke arrives after more than 25 years in healthcare leadership. Most recently, he was president of Help at Home, where he oversaw thousands of caregivers in a national in-home care operation. Before that, he spent 17 years at Humana, including work in Medicare Advantage and value-based care. He also previously served as chief executive of Ascension Complete, a multi-state provider-integrated Medicare Advantage plan.

Williams said the company had spent the past year rebuilding its operating base and that O’Rourke was chosen to carry that work forward. Founder and vice chairman Ravi Sachdev said O’Rourke’s background across both payors and providers matched Agilon’s model.

O’Rourke said Agilon’s recent changes in data and analytics, contracting discipline and cost management had created a stronger foundation for senior-patient care.

Agilon said it works with about 2,300 primary care physicians across approximately 30 communities. Today the company's shares have moved -0.42% to a price of $26.21. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS